Study Overview
A groundbreaking study led by researchers at the University of Texas at El Paso (UTEP) has revealed that popular weight-loss and diabetes drugs known as GLP-1 receptor agonists—such as Ozempic—may also help curb substance use disorders. Published in the peer-reviewed journal Frontiers in Psychiatry, the research analyzed over 142,000 patient records and found striking reductions in the risk of developing alcohol, opioid, nicotine, and cocaine use disorders among those prescribed GLP-1 medications.
Key Findings
The study, conducted by UTEP School of Pharmacy researchers Tadesse Abegaz, Ph.D., and Gabriel Frietze, Ph.D., examined data from patients with Type 2 diabetes or obesity. Of the total cohort, approximately 20,000 individuals were prescribed GLP-1 drugs. The team compared the incidence of substance use disorders between GLP-1 users and non-users, controlling for relevant variables.
Results showed that patients taking GLP-1 medications had:
- 74% lower odds of developing alcohol use disorder
- 69% lower odds of opioid use disorder
- 68% lower odds of nicotine use disorder
- 75% lower odds of cocaine use disorder
These findings suggest a robust association between GLP-1 use and reduced risk across multiple substance categories.
Mechanism of Action
GLP-1 receptor agonists were originally developed to manage blood sugar in Type 2 diabetes and to promote weight loss in obesity. However, emerging evidence indicates that these medications may influence brain pathways beyond metabolism. The UTEP researchers propose that GLP-1s could modulate dopamine signaling and other neural circuits involved in reward and craving. This mechanism might explain why patients on these drugs show lower rates of substance misuse.
“Our findings add to growing evidence that GLP-1 medications may influence more than appetite and blood sugar regulation,” said lead author Abegaz. “These medications appear to affect brain pathways involved in reward and craving, which could help explain the lower rates of substance use disorders observed in our study.”
Cautious Interpretation
Despite the promising results, the researchers emphasize that the study does not establish causation. The observational design means that other factors could account for the associations. For instance, patients prescribed GLP-1s may have different health behaviors or access to healthcare that independently reduce substance use risk.
“We do not support prescribing these medications for addiction treatment at this time,” said co-author Frietze. “Because this was an observational study in a specific clinical population, randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction.”
Implications and Future Research
The study adds to a growing body of literature exploring the non-metabolic effects of GLP-1 drugs. If confirmed in prospective trials, these findings could open new avenues for addiction treatment—a field that currently has limited pharmacological options. The UTEP team plans to conduct longitudinal research that follows individuals initiating GLP-1 therapy over time to better understand the relationship.
“Our next goal is to conduct prospective research that follows individuals initiating GLP-1 therapy over time,” the researchers stated. Such studies would help clarify whether the drugs directly reduce cravings or if the observed benefits stem from other factors.
Broader Context
GLP-1 medications have already revolutionized the treatment of obesity and diabetes, with drugs like Ozempic and Wegovy becoming household names. Their potential to address substance use disorders would represent a significant expansion of their therapeutic utility. However, experts caution that off-label prescribing for addiction is premature until rigorous clinical trials confirm efficacy and safety.
The study was peer-reviewed and published in a reputable journal, lending credibility to the findings. Nevertheless, the authors stress that the results should be interpreted with caution and that further research is essential.
Conclusion
The UTEP study provides compelling evidence that GLP-1 receptor agonists are associated with a substantially lower risk of developing alcohol, opioid, nicotine, and cocaine use disorders. While not yet ready for clinical application in addiction medicine, these findings highlight the potential of repurposing existing drugs for new indications. As the opioid epidemic and other substance abuse crises continue, any safe and effective treatment option would be welcome—but only after thorough validation.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
